Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results'

被引：0
|
作者：
Homer, N. [1 ]
Grewal, D. S. [1 ]
Mirza, R. G. [1 ]
Lyon, A. T. [1 ]
Gill, M. K. [1 ]
机构：
[1] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
EYE | 2015年 / 29卷 / 12期
关键词：
D O I：
10.1038/eye.2015.191
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：1630 / 1631
页数：3
相关论文
共 50 条
  • [21] One-year results of intravitreal aflibercept injections for neovascular age-related macular degeneration using a treat and extend regimen
    Hosokawa, Mio
    Morizane, Yuki
    Kimura, Shuhei
    Shiode, Yusuke
    Doi, Shinichiro
    Hirano, Masayuki
    Fujiwara, Atsushi
    Hosogi, Mika
    Shiraga, Fumio
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [22] Intravitreal aflibercept in neovascular age-related macular degeneration with limited response to ranibizumab: a treat and extend trial
    Hatz, Katja B.
    Pruente, Christian
    Binningen, Vistaklinik
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [23] A systematic review to assess the 'treat-and-extend' dosing regimen for neovascular age-related macular degeneration using ranibizumab
    Rufai, S. R.
    Almuhtaseb, H.
    Paul, R. M.
    Stuart, B. L.
    Kendrick, T.
    Lee, H.
    Lotery, A. J.
    EYE, 2017, 31 (09) : 1337 - 1344
  • [24] Mental Status and Feasibility of an Intravitreal Ranibizumab Treat-and-Extend Regimen in Patients with Neovascular Age-Related Macular Degeneration
    Kato, Aki
    Yasukawa, Tsutomu
    Sugita, Iichiro
    Yoshida, Munenori
    Nozaki, Miho
    Hirano, Yoshio
    Kondo, Junko
    Abe, Tomohiro
    Sugita, Kimiko
    Okita, Takahide
    Morita, Hiroshi
    Takase, Noriaki
    Ogura, Yuichiro
    ADVANCES IN THERAPY, 2022, 39 (03) : 1403 - 1416
  • [25] INJECTION FREQUENCY AND PROGNOSTIC FACTORS IN A TREAT-AND-EXTEND REGIMEN OF INTRAVITREAL RANIBIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Narayan, Daniel
    Muecke, James
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2013, 41 : 106 - 106
  • [26] A systematic review to assess the ‘treat-and-extend’ dosing regimen for neovascular age-related macular degeneration using ranibizumab
    S R Rufai
    H Almuhtaseb
    R M Paul
    B L Stuart
    T Kendrick
    H Lee
    A J Lotery
    Eye, 2017, 31 : 1337 - 1344
  • [27] EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION The ARIES Study: A Randomized Clinical Trial
    Mitchell, Paul
    Holz, Frank G.
    Hykin, Philip
    Midena, Edoardo
    Souied, Eric
    Allmeier, Helmut
    Lambrou, George
    Schmelter, Thomas
    Wolf, Sebastian
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2021, 41 (09): : 1911 - 1920
  • [28] Four-year outcomes of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a treat-and-extend regimen in Japanese patients
    Ishibashi, Koki
    Haruta, Masatoshi
    Ishibashi, Yumi
    Noda, Rie
    Dake, Shotaro
    Yoshida, Shigeo
    THERAPEUTIC ADVANCES IN OPHTHALMOLOGY, 2021, 13
  • [29] A modified treat-and-extend regimen of aflibercept for treatment-na⟨ve patients with neovascular age-related macular degeneration
    Ohnaka, Masayuki
    Nagai, Yoshimi
    Sho, Kenichiro
    Miki, Katsuaki
    Kimura, Motoki
    Chihara, Tomoyuki
    Takahashi, Kanji
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2017, 255 (04) : 657 - 664
  • [30] A modified treat-and-extend regimen of aflibercept for treatment-naïve patients with neovascular age-related macular degeneration
    Masayuki Ohnaka
    Yoshimi Nagai
    Kenichiro Sho
    Katsuaki Miki
    Motoki Kimura
    Tomoyuki Chihara
    Kanji Takahashi
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255 : 657 - 664
12345